Quadrivalent Recombinant Influenza Vaccine — Competitive Intelligence Brief

Quadrivalent Recombinant Influenza Vaccine (Quadrivalent Recombinant Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic

Target snapshot

Quadrivalent Recombinant Influenza Vaccine (Quadrivalent Recombinant Influenza Vaccine) — Sanofi Pasteur, a Sanofi Company. This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Quadrivalent Recombinant Influenza Vaccine TARGET	Quadrivalent Recombinant Influenza Vaccine	Sanofi Pasteur, a Sanofi Company	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
HPV9v	HPV9v	Fundacion SEIMC-GESIDA	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
HPV vaccine	HPV vaccine	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	Prophylactic vaccine	Human papillomavirus (HPV) capsid proteins / L1 antigen
Reinforced vaccination schedule	Reinforced vaccination schedule	Universidade Federal de Goias	marketed	vaccine
Pertussis containing vaccine	Pertussis containing vaccine	St George's, University of London	marketed	Bacterial vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class